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(D-Ser2)Oxm[Lys38-γ-glu-PAL] improves 
hippocampal gene expression and cognition  
in a mouse model of type 1 diabetes
Nupur Pathak1, Nigel Irwin2, Varun Pathak1, Victor Alan Gault1,  
Peter Raymond Flatt1
ABSTRACT
Objective: Oxyntomodulin (Oxm) is a gastrointestinal hormone with recently noted therapeutic potential for type 1 
diabetes mellitus (T1DM). The present study examined the effects of a stable Oxm analogue on anxiety, exploratory 
behavior, cognitive function, hippocampal gene expression and metabolic control in a mouse model of T1DM. 
Methods: Effects of twice daily administration of the stable Oxm analogue, (d-Ser2)Oxm[Lys38-γ-glu-PAL], was assessed 
in insulin-deficient streptozotocin (STZ)-induced T1DM mice. Results: Induction of diabetes by STZ injection significantly 
(P < 0.05) impaired learning and memory compared to normal control mice. However, (d-Ser2)Oxm[Lys38-γ-glu-PAL] 
treatment completely reversed this detrimental effect. Anxiety levels and exploratory behavior were not significantly 
different between all groups of mice. Hippocampal gene expression of MASH1, SYP and mTOR were reduced (P < 0.01 
to P < 0.001) in T1DM mice, but significantly (P < 0.05 to P < 0.001) enhanced by twice daily (d-Ser2)Oxm[Lys38-
γ-glu-PAL] intervention. Moreover, expression of SYP, mTOR and IRS-1 were significantly elevated (P < 0.05 to P < 
0.001) in (d-Ser2)Oxm[Lys38-γ-glu-PAL] mice compared to both STZ and lean controls. These effects were accompanied by 
improved (P < 0.001) glucose tolerance and insulin sensitivity compared to STZ controls. Conclusion: The data highlight 
the potential of (d-Ser2)Oxm[Lys38-γ-glu-PAL] for the treatment of T1DM, and reveal the ability of this Oxm analogue to 
restore the deficits of learning and memory observed in STZ-induced T1DM.
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Brief Report
INTRODUCTION
Oxyntomodulin (Oxm) is a proglucagon derived gut 
peptide secreted by enteroendocrine L-cells in response 
to feeding, which is known to activate both glucagon and 
GLP-1 receptors [1]. Accumulating evidence suggests that 
stable Oxm analogues represent an attractive potential 
therapeutic option for obesity and related metabolic disease 
[2]. As such, numerous studies confirm that through 
glucagon receptor activation, Oxm induces catabolic 
effects that favor weight loss, while glucose homeostasis 
is improved through activation of GLP-1 receptors [1]. 
To capitalize on this therapeutic profile, we have recently 
developed (d-Ser2)Oxm[Lys38-γ-glu-PAL], an enzymatically 
stable Oxm analogue, with a significantly a protracted in 
vivo biological action profile [3]. 
Despite a clear for use of stable Oxm analogues for the 
treatment of type 2 diabetes, effectiveness in insulin-
deficient type 1 diabetes mellitus (T1DM) is unknown. 
Thus, it might seem implausible that up-regulation of 
glucagon receptor signaling would be advantageous in 
T1DM. However, activation of GLP-1 receptors on both 
alpha- and beta-cells by Oxm would impart beneficial 
intraislet-cell effects in T1DM [4]. Indeed, we have recently 
shown that sustained treatment with (d-Ser2)Oxm[Lys38-γ-
glu-PAL] improves metabolic control and islet morphology 
in an experimental model of T1DM [5]. However, further 
observations from our laboratory reveal that Oxm-
mediated actions are not limited to the pancreas and gut, 
and that Oxm crosses the blood brain barrier [2]. As such, 
activation of Oxm signaling pathways in the hippocampal 
brain regions in an animal model of type 2 diabetes was 
associated with positive effects on cognitive function and 
overall learning and memory processes [2]. Therefore, we 
have now examined the consequence of twice daily (d-Ser2)
Oxm[Lys38-γ-glu-PAL] administration on metabolic status, 
anxiety, exploratory behavior, cognitive function and the 
expression of key hippocampal genes involved in learning 
and memory in insulin-deficient streptozotocin (STZ)-
induced T1DM mice. 
MATERIALS AND METHODS
Peptides 
(d-Ser2)Oxm[Lys38-γ-glu-PAL] was purchased from GL 
Biochem Ltd. (Shanghai, China) and characterized as 
described previously [3]. 
Animals 
Adult male NIH mice (14-16 weeks old; Harlan UK Ltd, 
Blackthorn, UK) were housed individually in an air-
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conditioned room at 22 ± 2°C with 12:12 h light/dark cycle. 
Mice had free access to drinking water and standard rodent 
maintenance diet that contained 10% fat, 30% protein 
and 60% carbohydrate (Trouw Nutrition, Cheshire, UK). 
Diabetes was induced by intraperitoneal (i.p.) injection 
of 12 h fasted mice with 150 mg/kg streptozotocin (STZ) 
freshly prepared in ice cold 0.1 M sodium citrate buffer, 
pH 4.5. All animal procedures were carried out according 
to the UK home office regulations (UK Animal Scientific 
Procedures Act 1986).
In vivo studies
Following STZ administration, mice (n=8) received twice 
daily injections (08:00 and 17:00 h) of saline vehicle (0.9% 
(w/v) NaCl) or (d-Ser2)Oxm[Lys38-γ-glu-PAL] (25 nmol/kg, 
b.w.) for 28 days. All STZ injected mice received insulin 
(15 U/kg b.w. once daily, bovine insulin, Sigma-Aldrich, 
Poole, UK) for the first 5 days of the study. Insulin therapy 
was only maintained thereafter in diabetic control mice. 
Normal mice maintained on standard diet, without STZ 
intervention, and treated twice daily with saline were used 
for comparative purposes. Body weight, non-fasting plasma 
glucose and insulin concentrations were recorded on day 
28. In addition, i.p. glucose tolerance (18 mmol/kg body 
wt) and insulin sensitivity (20 U/kg body wt) tests were 
performed at the end of the study period. 
Open field assessment and object recognition task 
For open field assessment, at the end of the study mice 
were placed in an exploratory arena (58 cm diameter, 
38 cm high) for 5 minute and a computerized tracking 
system (Biosignals, New York) analyzed measures of speed, 
distance travelled, rearing actions (indicator of exploratory 
activity) and grooming events (indicator of anxiety levels) 
[6]. For object recognition, animals were placed in the same 
arena and two identical random objects (2 marbles, 2.5 cm 
diameter; or 2 dice, 1.2 cm side length) were positioned in 
the center of the arena (dimensions outlined above). Four 
hours after initial exposure (the acquisition phase), one of 
the two objects was replaced by a novel object (a marble or 
dice) and the time spent exploring both objects during a 5 
minute trial phase determined. Recognition index (RI) was 
calculated as described previously [6].
Hippocampal gene expression
Whole hippocampus tissue was excised at the end of 
the treatment period, snap frozen and processed for 
gene expression by qPCR following total RNA extraction 
(Tripure Isolation Reagent; Roche Diagnostics, West 
Sussex, UK). cDNA was synthesized using Transcriptor 
First Strand cDNA Synthesis Kit (Roche Diagnostics). 
Gene expression analysis was carried out using a Roche 
Real Time ready qPCR assay and Light Cycler 480 Probes 
Master and a hot start reaction mix (Roche Diagnostics, 
West Sussex, UK), according to the Manufacturer’s 
instructions. The following target genes were designed 
and supplied by Roche (Roche Probe master): insulin 
receptor substrate-1 (IRS-1), synaptophysin (SYP); 
mammalian target of rapamycin (mTOR) and mammalian 
achaete-scute homologue 1 (MASH1). Gene expression 
was normalized to hypoxanthine guanine phosphoribosyl 
transferase (HPRT) expression and relative quantification 
assessed using the 2-ΔΔCT method to calculate differences in 
gene expression between samples, as described previously 
[2].
Statistical analysis
Results are presented as mean ± SEM.  Groups of data 
were compared using ANOVA and unpaired Student’s 
t-test in GraphPad PRISM (version 3.0).  Differences were 
considered significant if P < 0.05.
RESULTS
Effects of (d-Ser2)Oxm[Lys38-γ-glu-PAL] on metabolic 
control in STZ-induced diabetic mice
Twice daily treatment with (d-Ser2)Oxm[Lys38-γ-glu-
PAL] resulted in the complete normalization of body 
weight in STZ-induced diabetic mice by day 28 (Table 1). 
Non-fasting blood glucose and plasma insulin levels were 
still increased (P < 0.001) and decreased (P < 0.001), 
respectively, compared to normal control mice, but they 
were significantly improved (P < 0.01 and P < 0.001, 
respectively) compared to STZ diabetic controls (Table 
1), despite continued insulin therapy in STZ control mice. 
AUC glucose tolerance values were significantly (P < 
0.001) improved compared to STZ controls, but elevated 
(P < 0.001) when compared to normal control mice (Table 
1). In addition, the hypoglycemic action of insulin was 
significantly (P < 0.05) augmented in (d-Ser2)Oxm[Lys38-
γ-glu-PAL] treated mice compared to STZ diabetic 
controls (Table 1). 
Effects of (d-Ser2)Oxm[Lys38-γ-glu-PAL] on anxiety 
levels, exploratory behavior and hippocampal gene 
expression
Open field assessment revealed no effect of 28 days twice 
daily treatment with (d-Ser2)Oxm[Lys38-γ-glu-PAL] 
on the number of grooming (anxiety level) and rearing 
(exploration) episodes, as well as distance travelled and 
average speed, when compared to STZ and lean control 
mice (data not shown). However, STZ diabetic control mice 
had significantly (P < 0.05) impaired recognition memory 
by the end of the study, which was completely restored by 
(d-Ser2)Oxm[Lys38-γ-glu-PAL] treatment (Figure 1A, B). 
Indeed, (d-Ser2)Oxm[Lys38-γ-glu-PAL] mice displayed a 
similar preference to explore the novel object as normal 
control mice (Figure 1B). 
Pathak et al: Oxyntomodulin and insulin-deficiency
J Exp Integr Med ● 2016 ● Volume 6 ● Issue 1  3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
Effects  of  (d -Ser2)Oxm[Lys38-γ-glu-PAL] on 
hippocampal gene expression
Induction of diabetes by STZ injection significantly (P < 
0.01 to P < 0.001) reduced hippocampal gene expression 
of MASH1, SYP and mTOR (Figure 1C-E). (d-Ser2)
Oxm[Lys38-γ-glu-PAL] treatment significantly (P < 0.05) 
increased MASH1 expression compared to STZ diabetic 
control mice, although this was still lower (P < 0.05) than 
normal controls (Figure 1C). However, SPY and mTOR 
hippocampal gene expression was enhanced compared 
to both normal (P < 0.05 and P < 0.001; respectively) 
and diabetic (P < 0.001 in both cases) control mice 
(Figure 1D,E). STZ diabetic mice had unaltered IRS-1 
hippocampal gene expression, but treatment with (d-Ser2)
Table 1. Effects of (d-Ser2)Oxm[Lys38-γ-glu-PAL] on metabolic parameters in STZ-induced diabetic mice
Parameter STZ diabetic control (d-Ser2)Oxm[Lys38-γ-glu-PAL] Lean control
Body weight (g) 16.0 ± 0.2*** 19.5 ± 0.3ΔΔΔ  20.5 ± 0.3
Non-fasting glucose (mmol/l) 34.5 ± 1.1*** 25.7 ± 1.1***,ΔΔ  3.6 ± 0.2 
Non-fasting insulin  (ng/ml) 0.1 ± 0.1*** 0.6 ± 0.1***,ΔΔΔ           1.1 ± 0.1
Glucose tolerance: 0-60 min glucose 
AUC (mmol/l.min) 705.7 ± 47.0*** 526.7 ± 19.0***
,ΔΔΔ 331.1 ± 18.4
Insulin sensitivity: glucose 0-60 min AAC 
(mmol/l.min) 412.5 ± 67.2 808.2 ± 95.9
Δ 530.7 ± 179.0
Parameters were measured after 28 days treatment with saline vehicle or (d-Ser2)Oxm[Lys38-γ-glu-PAL] (25 nmol/kg).  For glucose tolerance, 
glucose (18 mmol/kg body wt) was administered in non-fasted mice and 0-60 min plasma glucose AUC values calculated. For insulin sensitivity, 
insulin (20 U/kg body wt) was administered in non-fasted mice and 0-60 min AAC values calculated. Values are mean ± SEM for six mice. ***P 
< 0.001 compared to normal lean controls. ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 compared to STZ diabetic controls maintained on insulin (15 U/kg 
b.w. once daily) throughout.
Figure 1. Effects of twice daily (d-Ser2)Oxm[Lys38-γ-glu-PAL] administration on (A, B) recognition index (RI) and (C-F) hippocampal gene 
expression in STZ-induced diabetic mice. (A, B) Recognition index (RI) was assessed during the acquisition (A) and test (B) tasks in mice. RI 
was defined as the amount of time exploring the familiar (tA) or novel object (tB) over the total time spent exploring both objects x 100: (tA or 
tB/(tA+tB))∗100. (C-F) mRNA expression of (C) MASH1, (D) SYP, (E) mTOR and (F) IRS-1 was examined in the hippocampus and expression 
normalized to levels of the internal control gene HPRT. All values are mean ± SEM for 5-7 mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared 
to normal controls. ΔP < 0.05, ΔΔΔP < 0.001 compared to STZ diabetic controls.
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Oxm[Lys38-γ-glu-PAL] increased expression compared to 
normal (P < 0.01) and diabetic (P < 0.05) control mice 
(Figure 1F).
DISCUSSION
Consistent with previous observations, up-regulation of 
Oxm signaling pathways resulted in marked beneficial 
effects in STZ-induced T1DM mice [4,5]. Thus, twice daily 
administration of (d-Ser2)Oxm[Lys38-γ-glu-PAL] markedly 
improved glucose homeostasis and insulin sensitivity. 
Notably, normalization of body weight was also observed 
in the current study, together with substantially reduced 
circulating glucose and increased insulin concentrations. 
We have already shown that these beneficial Oxm-
mediated effects are associated with improvements of islet 
morphology [5]. However, whilst encouraging effects of 
(d-Ser2)Oxm[Lys38-γ-glu-PAL] on cognition have recently 
been evidenced in type 2 diabetes [2], information in this 
regard is lacking in insulin-deficient T1DM. In view of the 
increasing awareness of cognitive defects in diabetes [7], 
we therefore examined the impact of (d-Ser2)Oxm[Lys38-
γ-glu-PAL] treatment on anxiety, exploratory behavior, 
recognition memory and the expression of key hippocampal 
genes involved in cognition in STZ-induced T1DM mice. 
In addition, recent evidence suggests a neuroprotective 
effect of Oxm in a mouse model of Parkinson’s disease [8].
In harmony with findings in high fat fed mice [2], 
treatment with (d-Ser2)Oxm[Lys38-γ-glu-PAL] resulted in 
a marked increase in hippocampal SYP gene expression 
in STZ-induced T1DM mice. This could point towards 
improved neuronal communication (synaptogenesis) in 
these mice [9], as expression was significantly elevated 
compared to both STZ-diabetic and lean control mice. In 
accordance with this, expression of MASH1, a molecule 
important for neuronal growth [10], was also enhanced 
in the hippocampus of (d-Ser2)Oxm[Lys38-γ-glu-PAL] 
treated STZ mice. As such, augmented MASH1 signaling 
indicates proliferation and differentiation of hippocampal 
progenitor neuronal cells [11]. Interestingly, sustained 
activation of GLP-1 receptors has also been shown to 
elevate hippocampal mRNA expression of MASH1 in 
mice [12]. Taken together, these observations suggest 
improvements in the processes underlying hippocampal-
mediated cognitive performance. Thus, (d-Ser2)Oxm[Lys38-
γ-glu-PAL] treated mice exhibited significantly increased 
learning and recognition memory, as evidenced by the novel 
object recognition behavioral task. Moreover, despite daily 
insulin therapy, STZ diabetic mice exhibited decreased 
recognition memory, highlighting the clear advantages 
of (d-Ser2)Oxm[Lys38-γ-glu-PAL] therapy in T1DM [5]. 
Importantly, improved memory was not associated with 
changes in anxiety or exploratory behavior, which could 
have otherwise impacted upon these findings. 
There is a recognized connection between the development 
of cognitive decline and insulin resistance [13]. Treatment 
with (d-Ser2)Oxm[Lys38-γ-glu-PAL] resulted in increased 
hippocampal mRNA expression of IRS-1, an important 
signaling protein responsible for initiating insulin and 
insulin-like growth factor signaling pathways [14]. As 
such, defective IRS-1 dependent insulin signaling in the 
hippocampus has been associated with severe cognitive 
deterioration [15]. Interestingly, hippocampal expression 
of mTOR, a protein kinase involved in the insulin signaling 
pathway [16], was prominently enhanced by (d-Ser2)
Oxm[Lys38-γ-glu-PAL] treatment. These observations 
suggest that the improvement of peripheral insulin 
sensitivity noted with (d-Ser2)Oxm[Lys38-γ-glu-PAL] 
also extends to its central actions. However, additional 
assessments of protein expression would also be important 
to more closely mimic a functional physiological effect for 
the genes described in this study.
In conclusion, the present study indicates that the 
therapeutic efficacy of (d-Ser2)Oxm[Lys38-γ-glu-PAL] in 
T1DM extends to enhancement of hippocampal signaling 
pathways involved in cognition and memory function [2]. 
The extent to which improvements in metabolic control 
contribute to these effects requires further clarification 
[17,18], but this study clearly highlights the potential of 
stable analogues of Oxm as novel therapeutic agents for 
alleviation of cognitive defects in T1DM.
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